



bewellconnect[®]

FDA-registered:

The French HealthTech ready to conquer the American market

Paris, October 26th, 2015

VISIOMED GROUP (FR0011067669 – ALVMG), a company specializing in new generation medical grade electronic products, is proud to announce that its first range of connected medical devices has been registered by the U.S. Food and Drug Administration (FDA). This major step now opens the way to marketing BewellConnect[®] products on the vast North American continent.

Eric Sebban, Founding Chairman and Chief Executive Officer of VISIOMED GROUP says: *"We obtained FDA registration of our first medical device this summer as planned, but wanted to wait to announce it until we had the major part of our product range authorized for sale in the United States. We now have considerable market clout with one of the most extensive and coherent product catalogs in the world of connected health. On the strength of this authorization, our operations center in Boston, and our discussions under way with top-tier partners, we are convinced we will make BewellConnect[®] the benchmark in connected health in the United States."*

To date, the BewellConnect[®] range of flagship products have received the necessary approvals (especially FDA 510k) and can therefore be marketed in the United States. These are:

- **MyGluco**, blood sugar meter;
- **MyGluco**, range of essential accessories (strips, sterile lances, control solution and lancing device);
- **MyTensio**, arm blood pressure monitor;
- **MyTensio**, wrist blood pressure monitor;
- **MyThermo**, thermometer with built-in patented contactless Thermo**Flash**[®] technology.¹
- **MyScale Initial**, weight scale;
- **MyScale Analyser**, body mass analyzer;
- **MyScale XL 200kg**, heavy weight scale;
- **MyCoach**, activity tracker and sleep analyzer.

¹ Thermo**Flash**[®] contactless thermometer is also approved for sale in the United States.



All these connected medical devices rolled out in the United States are linked to the BewellConnect® interpretive medical platform that complies with HIPAA² / HITECH³ standards for privacy and the confidentiality of health data.

The other flagship products in the range, particularly **MyECG**, **MyOxy** and **MyTens**, are still in the process of registration. VISIOMED GROUP expects them to be approved in the next few months.

The BewellConnect® brand has enjoyed high media exposure in the United States since its participation at the Las Vegas CES in January 2015. The Group boosted its local involvement in July with the opening of its subsidiary BewellConnect Corp USA in Boston and its participation in September in the Best of France event in Times Square, New York.

About VISIOMED GROUP

Founded in 2007 by Eric Sebban, VISIOMED GROUP specializes in new generation medical electronics. The laboratory develops and markets innovative health products in the booming field of medical and wellness self diagnosis devices. VISIOMED is notably the inventor of **ThermoFlash®**, the first-ever contactless infrared medical thermometer.

VISIOMED combines innovation, technology and design to provide non-drug solutions for prevention and treatment focused on simplicity, comfort and the wellbeing of users.

In 2014, VISIOMED GROUP announced the launch of its range of BewellConnect® connected health products, thus becoming the first medical electronics laboratory to penetrate the very-high-potential IoT market (Internet-of-Things). Based in Paris, VISIOMED GROUP is backed by a team of 105 staff including sales teams dedicated to marketing to pharmacies (OTC), to health professionals (hospitals, clinics, retirement homes) and, since late 2010, to large retailers. Group sales in 2014 were more than €13 million. VISIOMED GROUP is recognized as an “Innovative Enterprise” by Bpifrance.

VISIOMED GROUP won national 2nd place in the 2014 Deloitte In Extenso Technology Fast 50 rankings, and European 2nd place in the Health/Biotech/Pharma sector Deloitte Technology Fast 500 rankings.

For more information go to www.visiomed-lab.com.

CONTACTS

VISIOMED GROUP

Eric Sebban

bourse@visiomed-lab.com

Chairman & CEO

+33 (0)1 40 67 06 50



TRENT & COMPANY INC.

Pamela Wadler

pam@trentandcompany.com

Press Relations

+1 212 966-0024



² U.S. Health Insurance Portability and Accountability Act

³ U.S. Health Information Technology for Economic and Clinical Health Act



New generation medical technology